CoChat

Prevalence and Healthcare Burden of Fungal Infections in the United States, 2018

Open access
Rayens, Emily, Norris, Karen A · 2022 · Open Forum Infectious Diseases

The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet; 16 of the 32 sources its claims cite were checked for support.

Abstract

BACKGROUND: Fungal infections are responsible for >1.5 million deaths globally per year, primarily in those with compromised immune function. This is concerning as the number of immunocompromised patients, especially in those without human immunodeficiency virus (HIV), has risen in the past decade. The purpose of this analysis was to provide the current prevalence and impact of fungal disease in the United States. METHODS: We analyzed hospital discharge data from the most recent (2018) Healthcare Cost and Utilization Project National Inpatient Sample, and outpatient visit data from the National Ambulatory Medical Care Survey and the National Hospital Ambulatory Medical Care Survey. Costs are presented in 2018 United States (US) dollars. RESULTS: infections accounted for 76.3% of fungal infections diagnosed, and 81.1% of associated costs. Most fungal disease occurred in patients with elevated risk of infection. The visit costs, lengths of stay, and risks of mortality in this population were more than twice that of those without fungal diagnoses. A further 6.6 million fungal infections were diagnosed during outpatient visits. CONCLUSIONS: Fungal disease is a serious clinical concern with substantial healthcare costs and significant increases in morbidity and mortality, particularly among predisposed patients. Increased surveillance, standardized treatment guidelines, and improvement in diagnostics and therapeutics are needed to support the rising numbers of at-risk patients.

Verified 2026-11-19 · 1 reference not checked yet

Overview

CoChat Summary

TL;DR

In 2018, an estimated 666,235 fungal infections were diagnosed during 35.5 million US inpatient visits, with an estimated attributable cost of $6.7 billion and a further 6.6 million fungal infections diagnosed in outpatient visits. Fungal diagnoses were associated with roughly doubled visit costs, lengths of stay, and mortality risk, especially in patients with predisposing conditions.

Key findings

  • Among 35.5 million inpatient visits in 2018, 666,235 fungal infections were diagnosed; Aspergillus, Pneumocystis, and Candida infections accounted for 76.3% of diagnosed fungal infections and 81.1% of associated costs.
  • The mean cost of an inpatient visit with a fungal diagnosis was $55,418 versus about $24,560 for an average inpatient visit; total costs for all visits with any fungal diagnosis were $37.7 billion, while visits with fungal disease as the primary cause totaled $1.4 billion.
  • Approximately 32,560 deaths occurred in patients with any fungal diagnosis, and about 1,440 deaths occurred in patients admitted for fungal infections; highest mortality was seen with mucormycosis (18.6%) and invasive candidiasis (17.0%).
  • In at-risk patients, fungal infection was associated with doubled average cost ($59,490 vs $29,700), doubled length of stay, and increased mortality risk; low-risk patients had fewer fungal infections (123,235; 18.50%) but at least as severe impacts.

Methods

  • Analyzed 2018 Healthcare Cost and Utilization Project National Inpatient Sample hospital discharge data and 2016–2018 National Ambulatory Medical Care Survey / National Hospital Ambulatory Medical Care Survey outpatient visit data.
  • Used ICD-10 codes to identify fungal infections and at-risk conditions, APR-DRG severity and mortality risk measures, and Elixhauser Comorbidity Index codes; costs are presented in 2018 US dollars using NIS cost-to-charge ratios.
  • Statistical analyses were performed with SAS version 9.4; maps were generated with Datawrapper and presented by region rather than state per HCUP guidelines.

Limitations

  • The paper states the true burden is likely greater than estimated: only half of invasive fungal infections are diagnosed before death, HCUP and NAMCS/NHAMCS cannot identify unique patients so prevalence rather than incidence is captured, and average costs and mortality may be underestimated because multiple visits may belong to one patient.
  • The paper also notes NAMCS/NHAMCS may underestimate outpatient fungal infections because laboratory-test diagnoses may not be captured on the visit day, the 2014 comparison used ICD-9-CM while 2018 used ICD-10-CM, many cases were coded as “unspecified mycoses,” and procedures such as surgeries or central venous catheters were not incorporated as risk conditions.
  • Evident from the text: reliance on administrative diagnosis codes may misclassify or undercount infections, and some “low-risk” patients may have unlisted risk conditions or procedures not captured in the dataset.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1093/ofid/ofab593

Cites

38 of 39 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1. Rate of fungal infections and associated risk condition diagnoses in the United States in 2018. The diagnostic rates per 100 000 inpatient visits of conditions associated with elevated risk of fungal disease (A), all fungal infections (B), invasive fungal infections (C), and noninvasive fungal infections (D). Rates are presented by geographic region.
Figure 1. Rate of fungal infections and associated risk condition diagnoses in the United States in 2018. The diagnostic rates per 100 000 inpatient visits of conditions associated with elevated risk of fungal disease (A), all fungal infections (B), invasive fungal infections (C), and noninvasive fungal infections (D). Rates are presented by geographic region.CC BY-NC-ND · PubMed Central
Figure 2. Changes in fungal disease diagnoses and direct costs between 2014 and 2018. The difference in the number of fungal infections diagnosed during inpatient visits (A) and the direct costs of these visits (B). Abbreviation: USD, United States dollars.
Figure 2. Changes in fungal disease diagnoses and direct costs between 2014 and 2018. The difference in the number of fungal infections diagnosed during inpatient visits (A) and the direct costs of these visits (B). Abbreviation: USD, United States dollars.CC BY-NC-ND · PubMed Central
Figure 3. Changes in fungal disease diagnoses and direct costs between 2014 and 2018. The ratio of average cost of inpatient visit, average length of stay, and relative risk of mortality associated with fungal diagnosis in patients with (A) and without (B) diagnosis of risk conditions associated with increased risk of fungal disease.
Figure 3. Changes in fungal disease diagnoses and direct costs between 2014 and 2018. The ratio of average cost of inpatient visit, average length of stay, and relative risk of mortality associated with fungal diagnosis in patients with (A) and without (B) diagnosis of risk conditions associated with increased risk of fungal disease.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

12 Valid · 1 Not valid · 14 Not checked · 108 Own results and interpretations

94 more claims

Create a free account to see all 135 claims and to verify the 4 references still open.

See all claims — free account
  • It may state two separate claims as one. 25
  • Probably not a substantial claim. 13
  • The quote only partly states this claim. 2

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

5 of 15 · the rest aren’t loaded

10 more findings

Create a free account to see every finding of this check.

See all findings — free account

Citations

Cites

Cited by

See all 228

Metadata

Authors
Rayens, E., & Norris, K. A.
Affiliations
University of Georgia (US)
Corresponding author
Rayens, Emily
Venue
Open Forum Infectious Diseases
Published
2022-01-01
Volume
9
Issue
1
Pages
ofab593-ofab593
ISSN
2328-8957 (ISSN-L)
OpenAlex
W4206237820
Cited by
228
References
40
Citations by year
2026: 40 · 2025: 71 · 2024: 54 · 2023: 49 · 2022: 14
FWCI
22.94
Type
journal article
Language
en
Open access
Locations
  • Open Forum Infectious Diseases (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health (1R01 AI148365-01A1)
  • University of Georgia Research Foundation
Topics
  • Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
  • Health Sciences › Medicine › Infectious Diseases › Fungal Infections and Studies
  • Health Sciences › Medicine › Dermatology › Nail Diseases and Treatments
Keywords
fungal infection, prevalence, healthcare burden, health care costs, hospitalization, outpatient visits, immunocompromised patients, mortality, length of hospital stay, risk factors, United States

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol and qwen3.8-omni-flash).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.